U.S. pharma big copyright scrapped two experimental weight loss capsules past 12 months—a when-each day tablet, lotiglipron, because of elevated liver enzymes as well as a 2 times-day-to-day capsule, danuglipron, as a consequence of powerful Unwanted side effects—but CEO Albert Bourla has claimed the company is decided to “play and acquire”